Renata Medical Secures $25M Series D Financing to Expand Pediatric Cardiovascular Technologies
Renata Medical, a medical technology company focused on pediatric cardiovascular care, has closed a $25 million Series D financing round led by ARCHIMED. The funding will support the expansion of its Minima™ Stent System in U.S. and international markets, development of new technologies for congenital heart disease (CHD), and clinical research as adoption grows. The Minima™ Stent System received FDA premarket approval in August 2024 and was granted a New Technology Add-on Payment designation by CMS in August 2025. This reimbursement support is expected to facilitate broader hospital adoption of the device, which addresses unmet needs for neonates and young children with pulmonary artery stenosis or coarctation. ARCHIMED's Managing Partner André-Michel Ballester praised Renata’s innovation as a solution that could transform pediatric care. The company was founded in 2019 to develop cardiovascular devices tailored specifically for children, aiming to reduce the need for repeated procedures due to implant growth limitations.
Topics: congenital_heart_disease medical_technology pediatric_care